Specifically, IL‐25 stimulation enhanced ILC2‐driven recruitment of MDSCs, which inhibit CD8+ T cell activity and accelerate tumour growth; blocking this IL‐25/ILC2 axis reverses immunosuppression and reduces tumour burden, highlighting its therapeutic potential [97]. The gene discussed is CD8A; the disease is neoplasm.